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Abstract
Quantifying the value of investment in medical research can inform decision-making on the
prioritisation of research programmes. Existing methodologies to estimate the rate of return
of medical research are inappropriate for early-phase translational research due to censor-
ing of health benefits and time lags. A strategy to improve the process of translational
research for patient benefit has been initiated as part of the UK National Institute for Health
Research (NIHR) investment in Biomedical Research Centres (BRCs) in England. By pro-
viding a platform for partnership between universities, NHS trusts and industry, successful
BRCs should reduce time lags within translational research whilst also providing an impetus
for local economic growth through industry collaboration. We present a novel contribution in
the assessment of early-phase biomedical research by estimating the impact of the Oxford
Biomedical Research Centre (OxBRC) on income and job creation following the initial NIHR
investment. We adopt a macroeconomic assessment approach using Input-Output Analysis
to estimate the value of medical research in terms of income and job creation during the
early pathway towards translational biomedical research. Inter-industry linkages are
assessed by building a model economy for the South East England region to estimate the
return on investment of the OxBRC. The results from the input-output model estimate that
the return on investment in biomedical research within the OxBRC is 46%. Each £1 invested
in the OxBRC generates an additional £0.46 through income and job creation alone. Multipli-
cative employment effects following a marginal investment in the OxBRC of £98m during
the period 2007-2017 result in an estimated additional 196 full time equivalent positions
being created within the local economy on top of direct employment within OxBRC. Results
from input-output analyses can be used to inform the prioritisation of biomedical research
programmes when compared against national minimum thresholds of investment.
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Introduction
Economic assessments of the impact of medical research aim to capture the direct health
benefits to patients, the health system and wider economy. Direct health benefits following
investment in medical research include improvements in patient treatment and diagnosis,
advancement of scientific knowledge as well as process changes associated with clinical deci-
sion making and health care delivery. Quantifying the value of medical research is an impor-
tant feature of translational research to inform decision-making on the prioritisation of
research programmes. The aim of this paper is to outline a methodology for valuing the return
on investment of early-phase translational biomedical research. Existing methodologies on
medical research impact are constrained by a paucity of data on direct health benefits during
early-phase research as well as time lags associated with the translational research process. We
use income and job creation as surrogate outcomes for the economic value of medical research
during early-phase biomedical research with censored health benefits.
The National Institute for Health Research (NIHR) established the first phase of Biomedical
Research Centres (BRCs) in England in 2007 for an initial 5 year period, with the second
round of funding initiated in 2012. In the Chancellor’s spending review in the UK in late
November 2015, George Osborne protected funding for the third phase of competitive funding
for BRCs. The third phase commenced for successful BRCs in spring 2017 as part of the UK
Government’s strategy to improve the process of translational research for patient benefit. It is,
therefore, timely to evaluate the economic impact of the Oxford BRC (OxBRC). By providing
a platform for partnership between universities, NHS trusts and industry, successful BRCs
should reduce time lags within translational research whilst also providing an impetus for local
economic growth through industry collaboration.
A number of methodologies exist for measuring research impact (See [1–3] for recent
reviews). The Payback Framework developed by Buxton and Hanney [4] represents one prom-
inent approach which has been widely applied to estimate the impact of medical research. A
key feature of the framework is a non-linear seven stage research process with linkages
between research and wider social, political and economic environments. An intuitive appeal
of Buxton and Hanney’s payback framework is the ability to capture the full life-cycle of bio-
medical research from initial research idea inception (Stage 0) to measurement of health, eco-
nomic and societal benefits (Stage 6). Extensions of the framework have been adopted by
Hanney et al. [5] and Wooding et al. [6] for early phase biomedical research. One limitation of
the extensions of the Framework for early phase biomedical research is the time lag associated
with translational biomedical research. Morris, Wooding and Grant [7] consider the evidence
of the frequently reported 17 year time lag of translational research and note the limitations of
using a reported average time lag due to substantial heterogeneity. Although a motivation for
investment in BRCs is to streamline the translational research process, dissemination of out-
puts from existing research programmes across BRCs may not have fully matured in a clinical
environment within that time period. Evidence to support estimated rates of return within the
existing literature are dependent on large time-series data in excess of 20 years to ensure
appropriate measurement of both clinical and wider economic outcomes (See, for example,
Glover et al. [8]). A central question of this paper is how to measure the returns on medical
research when health benefits are yet to be realised as part of early-phase research
programmes.
The pathway to translational research is commonly characterised as a two stage process.
Type-I translational research is concerned with product development by generating the evi-
dence base from in-vitro pre-clinical testing through to potential implementation in routine
clinical care. Type-II translational research focuses upon the implementation stage of products
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which have shown clinical promise as demonstrated by the Type-I empirical evidence. A
microeconomic assessment of changes in health represents a natural starting point for estimat-
ing the value of medical research. This micro or “bottom-up” approach aims to first identify
the health benefits to the patients as well as isolating linkages with the private sector to capture
wider spillover effects to the economy. A bibliometric analysis represents one methodology for
very late stage Type-I as well as Type-II translational research outputs. This approach may also
synthesise the bibliometric analysis with qualitative approaches with key personnel to elicit
achievements and linkages with industry and policy to offer a more comprehensive assessment
of research impact. It is clear that this microeconomic approach is problematic for early-phase
biomedical research in which health benefits are yet to be realised. Other important consider-
ations can be identified and measured during intermediate steps on the pathway to transla-
tional research in light of the role of BRCs as a stimulus for local economic growth. This paper
presents a methodology for estimating the economic value of medical research during Type-I
biomedical translational research. Using NIHR Oxford Biomedical Research Centre (OxBRC)
as an exemplar, we outline the appeal of input-output model multipliers to estimate income
and job creation.
To capture the value of early phase biomedical research, this paper will focus exclusively on
income and job creation following NIHR investment in the OxBRC. To ensure estimates on
the return on investment avoid double-counting, we exclude subsequent public research fund-
ing secured following the introduction of the OxBRC. Buxton et al. [9] estimate that the inter-
nal rate of return of UK cardiovascular disease research to be 39% during the period 1975 to
2005. Only 9% of the internal rate of return was attributable to health benefits with the remain-
ing 30% derived from wider economic effects. The magnitude of the economic returns relative
to the health benefits provides motivation for the focus on income and job creation during the
intermediate stages of Type-1 translational biomedical research. Raftery et al. [10] categorises
the existing empirical literature on research impact into 20 different methodologies with vary-
ing definitions of impact and scope. Direct comparisons across methodologies used in the
existing literature are constrained as inputs and outputs on the return on investment are not
commensurate. We present a methodology for measuring research impact which ensures
input and output data are commensurate across research programmes and disease areas. By
ensuring all outputs are a multiplicative effect of all inputs, the methodology addresses con-
cerns about macroeconomic assessments of research impact, such as double-counting and
over inflated estimates of return on investment.
Materials and methods
Economic model and statistical methods
We propose a macroeconomic assessment or “top-down” approach using Input-Output Anal-
ysis to estimate the value of medical research in terms of income and job creation during the
early pathway towards translational biomedical research. Input-output models are simplifica-
tions of a representative economy and can be used at any spatial level from an individual
industry to the global economy. Leontief [11, 12] outlined the appeal of Input-Output analysis
as a matrix of supply and consumption dependencies across industries within an economy.
The system of equations for the model economy can be expressed in matrix form as:
x ¼ Axþ y ð1Þ
where x represents a column vector of sectoral supply of goods and services, y represents a col-
umn vector of inter-industry use of goods and services to produce an output for the respective
industry and A is a technology matrix, in this case, derived from the inter-industry transaction
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table for the South East England economy. The solution matrix following a vector of industry
changes in demand from an income injection, y, which ensures inter-industry demand and
supply are equalised, can be expressed as:
x ¼ ðI   AÞ  1y ð2Þ
where I represents the identity matrix, (I − A)−1 is the inverse of (I − A) and economic
coefficients for the input-output model are derived by (I − A)−1 [13]. The broad industry clas-
sification used to construct the Input-Output model are reported in S1 Table with the corre-
sponding technical coefficients and interdependencies across industrial sectors reported in S2
Table. By constructing a model economy in this way, input-output models aim to assess the
interdependence among the different sectors of the economy. The input-output methodology
is widely used by government agencies when producing national economic accounts as well as
for the assessment of large scale (dis)investment decisions at regional levels. A primary motiva-
tion for the use of input-output models is that the effect of a change in demand is not simply
confined to an individual industry. Instead, there will often be diffusion and spillover effects to
other industries within the economy as well as positive externalities to individuals and house-
holds. Although input-output analysis has been previously applied, we present a novel contri-
bution in the assessment of early-phase biomedical research by estimating the economic
research impact.
Outcomes
We aim to assess the economic impact of an investment in early phase biomedical research to
the OxBRC. An output multiplier will be obtained from the input-output model to estimate
the economic return on investment during the period 2007-2017, synthesising three types of
economic effects. The direct effect can be defined as the initial change in income and jobs cre-
ated following the introduction of the OxBRC. Indirect effects capture the secondary changes
in demand across all industrial sectors attributable to the direct effect. Induced effects are the
added value from changes in consumption following increased employees’ spending given the
indirect effect. The measurement of outcomes is confined to income and job creation follow-
ing investment in the OxBRC. To derive marginal effects, the initial investment in OxBRC
during 2007-2012 is excluded in the input-output analysis. The inclusion of this period would
overestimate the rate of return due to the consolidation of existing personnel, equipment and
research outputs during the establishment phase of OxBRC. As an illustration of the appeal of
input-output methods to quantify the value of early-phase biomedical research, the additional
demand generated for the period 2007-2017 is estimated to be of the magnitude of £98m rather
than the total direct investment of £157m over the full period. Direct, indirect and induced
effects of the OxBRC on job creation are estimated using Type-I and Type-II employment
multipliers derived from the input-output model for the South East England economy.
Data source
The input-output model and derivation of multiplier effects reflect a mixture of regional and
national estimates of economic activity. Industry supply and use tables for the UK were
obtained from the Office for National Statistics (ONS). Individual industries were aggregated
into 10 broad industry classifications to allow more meaningful insights into inter-industry
dependency. Variable definitions for each of the 10 industries as well as disaggregated industry
components are reported in S1 Table. Technical coefficients for the input-output matrix were
calibrated for the South East England region (excluding London) to ensure estimates of impact
were proportional to the local economy. Gross value added per capita for the Oxfordshire
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region were obtained from the Office for National Statistics (Nomis). Employment and finan-
cial data from the OxBRC were used to deduct the consolidation period during Phase 1 (2007-
2012) of the BRC but the estimated return on investment from the input-output analysis is
based on the full implementation period (2007-2017) to provide provisional estimates of
impact.
Results
Fig 1 presents the transaction table of sales and payments for the South East England regional
economy. Each column captures the inter-industry relationship following a change in demand
in each of the 10 industrial sectors. The size of each bubble is weighted by the relative indus-
try’s contribution in the production of those goods and services. In this setting, the larger the
bubble within each column the greater the dependency on that industrial sector as a primary
supplier in the production process. Each industry is dependent on other sectors of the local
economy when producing goods and services. Multiplicative effects of a change in demand
within an individual sector in the local economy occur through inter-industry collaboration as
well as supply from other firms in order to produce the goods and services. Production, profes-
sional service and other health industries are the largest beneficiaries in the production of
goods and services within the health industry. Each row captures the relative magnitude of
sales across other industries within the local economy. For example, goods and services pro-
duced within the health industry are predominately purchased by other firms within the health
industry whereas the production industry relies on the agriculture, construction, distribution
as well as other firms within the production industry.
The results from the input-output model estimate that the rate of return on investment in
biomedical research within the OxBRC is 46%. That is, each additional £1 invested in the
OxBRC generates £0.46 through income and job creation alone. A schematic of the diffusion
across the 10 industries following an initial £98m investment in the health sector for the
OxBRC would be unwieldy and difficult to interpret. As a result, Fig 2 illustrates the results for
key beneficiary industries of the health sector for two iterations of changing demand and sup-
ply across the sectors. An initial £98m injection into the health industry generates a £10.1m,
£9.4m and £4.4m increase in the production, health and professional service industries,
Fig 1. Supply and use matrix for the South East England regional economy. A balloon plot for the relative contribution of each
industry to the wider regional economy.
https://doi.org/10.1371/journal.pone.0214361.g001
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respectively. The first round stimulus occurs as goods and services produced by the produc-
tion, professional service sector and other health industries are used to provide goods and ser-
vices within the health sector. Second round multiplicative effects occur as demand for goods
and services within the beneficiary industries also increases following the first round direct
injection.
The £10.1m injection into the production sector increases supply for other firms of the pro-
duction industry by a further £2.5m, £7,500 in the health sector and £188,000 in the profes-
sional services industry. The small magnitude for the health sector is supported by Fig 1 in
which the production industry is not dependent on health when producing goods and services.
A cyclical process of inter-industry demand and supply filters through the local economy until
an equilibrium is reached when demand is saturated across all industries.
The effect of inter-industry changes in demand will also have a direct, indirect and induced
effect on employment to meet the increased demand. Multiplicative employment effects
derived from the input-output model estimate that 476 [range: 459-492] full time equivalent
jobs will be supported and created following the initial £98m investment in OxBRC within the
Fig 2. Diffusion and inter-industry spillover effects following the initial marginal investment in OxBRC for selected key
industries. A schematic of the diffusion of partial economic effects for key industries following an initial investment in the regional
health sector.
https://doi.org/10.1371/journal.pone.0214361.g002
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economy. This includes the direct employment within OxBRC, indirect jobs created within
beneficiary industries of health and education as well as induced job generation from increases
in regional income following industry demand and supply changes. After deducting direct
OxBRC employment, the marginal effect on employment is an additional 196 full time equiva-
lent positions created following the investment in OxBRC.
Discussion
We present a flexible methodology for estimating the economic impact of early-phase biomed-
ical research. The results on income and job creation from the input-output model signify the
OxBRCs role as an engine for economic growth within the regional economy. An additional
196 full time equivalent external positions are created across the region through the establish-
ment of the OxBRC as well as £46m generated by stimulating demand across industrial sectors.
The input-output model does not capture additional paybacks, such as population health bene-
fits as well as the generation of external research grant income as a result of the marginal effects
of NIHR investment in OxBRC. A key rationale for the focus on income and job creation
relates to the role of BRCs as providing a platform for clinical research and industry collabora-
tion for patient benefits. Aggregating NIHR funding to BRC institutions as a means of deriving
initial estimates of input for an input-output model would result in inflated estimates of
impact. Instead, input parameters should be calculated as the marginal effect of NIHR invest-
ment after discounting for existing personnel, equipment, research outputs as well as adjust-
ments for local wage inflation and living weighting allowances. The estimated return on
investment for OxBRC can be considered a partial assessment and will require updating once
health benefits have come to fruition across the full life cycle of the BRC inclusive of transla-
tional lagged effects.
The existing payback literature on the value of medical research highlights the dispropor-
tional impact of economic benefits in the calculation of rates of return. For example, Buxton
et al. [9] estimate that internal rate of return of UK cardiovascular disease research to be 39%,
with economic benefits accounting for 76% of the effect over the period 1975 to 2005. Glover
et al. [8] estimate the rate of return of cancer research to be 40% with economic effects more
than three times the magnitude of the health benefits. The estimated economic return on
investment of 46% for OxBRC for income and job creation alone is greater in magnitude
than the reported economic and health benefits. One explanation for this result relates to the
role of BRCs in streamlining the translational research process and promotion of industry col-
laboration. The estimated results for the return on investment for OxBRC exceed the UK gov-
ernment’s minimum threshold of 3.5% for investments and, therefore, provide economic
justification for the continued investment in OxBRC.
Existing top-down methodologies for valuing medical research may result in over-inflated
estimates of impact. Deloitte Access Economics [14] estimate the return on Australian
National Health and Medical Research Council investment in cardiovascular disease over the
period 2000-2011 to be 509%. Access Economics [15] quantify the returns from all Australian
Research and Development (R&D) funding over the period 1992-2005 to be in the region of
110%. The magnitude of some reported returns on investment should be interpreted with cau-
tion, and concern that policy makers may be unrealistically primed for returns on medical
investment in excess of 100%. Murphy and Topel [16, 17] estimate the return of biomedical
R&D in the US in 1995 on health improvements to exceed $2 trillion per year using conserva-
tive estimates on the value of a statistical life. We present a unified methodology for valuing
early-phase biomedical research that is accessible to policy makers and appropriate for
Macroeconomic assessment of medical research expenditure
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capturing intermediate outcomes on the translational pathway. Although a top-down
approach, the estimated return on investment using the input-output methodology is similar
in magnitude to other microeconomic methods. This provides a robustness check of the
reported estimates and ensures the presented methodology is not biased by double-counting
of research activity and impact.
There are potential limitations associated with the input-output methodology. Input-out-
put analyses are dependent on the quality of input parameters and magnitude of multiplier
effects. The use of national, regional or local economic estimates on supply and use across
industries is not without its challenges and limitations. In the absence of local economic input
data, careful consideration about appropriate spatial estimates at the national and regional
level is needed to ensure generalisability is maintained at the local level. We use Supply and
Use data for the South East England regional economy but exclude London as the industry
case-mix for London is considered inappropriate for Oxford and, potentially, unrepresenta-
tive of the South East England economy as a whole. Results derived from input-output analy-
ses can be considered to be based on deductive reasoning in which historical data on inter-
industry linkages are used to predict changes in the local economy. Within this framework,
trade between industries in the past is implicitly assumed to be the best indicator of trade in
the future. Although this may not appear too strong an assumption, any structural shifts
within an economy may result in current trends that deviate from historical patterns of activ-
ity. The result following the 2016 UK European Union (EU) membership referendum would
fall into this category depending on the nature of the UK’s EU exit in which pre-2016 eco-
nomic activity may not provide a useful indicator for a post-EU UK. Data collection on local
economic inter-industry linkages would be needed in the absence of robust historical Supply
and Use tables.
The OxBRC is used as an exemplar to highlight the appeal and application of input-output
analysis with multiplier effects in estimating the value of early-phase biomedical research.
Although the present analysis is confined to the South East England regional economy using a
linear deterministic input-output model, the methods are flexible enough to be applied in the
evaluation across all NIHR BRCs using dynamic or non-linear input-output methods. If, how-
ever, the research question is concerned with the evaluation of all medical research undertaken
by a particular funding agency then extensions of the input-output methodology would be
fruitful. This may include the adoption of a Social Accounting Matrix and General Equilib-
rium Modelling methodologies.
Conclusion
Existing top-down methodologies for valuing medical research result in over-inflated esti-
mates while microeconomic assessments are constrained by censored benefits. Input-output
analysis overcomes these limitations resulting in unbiased estimates while ensuring that the
true value of early-phase biomedical research is greater than the sum of the parts. We exclude
subsequent public research funding secured following the introduction of the OxBRC to avoid
double-counting as some of this activity would have occurred independent of the expenditure
on the OxBRC. The results, therefore, represent conservative estimates on the return on invest-
ment. As our results are generated using data for the South East England regional economy,
the generalisability to differing spatial contexts should apply the top-down methodology using
relevant local data. The estimated results of the return on investment for OxBRC exceed the
UK Government’s minimum threshold of 3.5% for investments and, therefore, provide eco-
nomic justification for the continued investment in OxBRC.
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